Alzheimer's Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Eisai, Hoffmann-La Roche, AZ Therapies, Neurotrope bioscience, AZ Therapies

The Key Alzheimer's Disease Companies in the market include - Eisai Inc., Hoffmann-La Roche, AZ Therapies, Neurotrope bioscience, AZ Therapies, Cerecin, and others.

The Alzheimer's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alzheimer's Disease pipeline products will significantly revolutionize the Alzheimer's Disease market dynamics.

DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Alzheimer's Disease, historical and forecasted epidemiology as well as the Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alzheimer's Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Alzheimer's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alzheimer's Disease Market Insights [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Alzheimer's Disease Market Report:

*
The Alzheimer's Disease market size was valued ~USD 3,610 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In October 2024, Annovis Bio Inc. announced that it successfully completed an End-of-Phase 2 meeting with the FDA for its Alzheimer's drug, buntanetap. The FDA has approved the progression to Phase 3 pivotal trials, following data demonstrating symptomatic improvement in patients with early Alzheimer's. Annovis is now poised to file New Drug Applications (NDAs) for both short-term and long-term efficacy in treating early Alzheimer's disease.

*
In September 2024, Eli Lilly's Alzheimer's treatment, Kisunla (donanemab), has been approved in Japan, following its U.S. approval in July. Kisunla becomes the second amyloid-targeting therapy approved in Japan, after Eisai and Biogen's Leqembi (lecanemab). It is indicated for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and mild dementia, who have confirmed amyloid pathology.

*
In 2023, the United States represented the largest market for Alzheimer's disease, accounting for approximately 54% of the total market size across the 7MM, compared to other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

*
In 2023, Germany had the largest market size for Alzheimer's disease among the EU countries, with USD 267 million, while the UK had the smallest market size, approximately USD 104 million.

*
In 2023, the market size for Alzheimer's disease in Japan was estimated to be approximately USD 845 million.

*
According to DelveInsight's assessment, the total diagnosed prevalent cases of Alzheimer's disease in Japan were estimated to be approximately 3.92 million in 2023.

*
In 2023, the United States accounted for about 44% of the diagnosed Alzheimer's disease cases across the 7MM, with approximately 6.98 million cases. This number is expected to grow by 2034, according to DelveInsight's estimates.

*
In Japan, there were approximately 1.39 million diagnosed male cases and 2.53 million diagnosed female cases of Alzheimer's disease in 2023, reflecting the gender distribution within the population.

*
In the US, age-specific cases of Alzheimer's disease are divided into four groups: under 65, 65-74, 75-84, and 85+ years. In 2023, the 75-84 age group had the highest prevalence, with approximately 2.79 million cases, while the under-65 group had the lowest, with around 175 thousand cases.

*
Key Alzheimer's Disease Companies: Eisai Inc., Hoffmann-La Roche, AZ Therapies, Neurotrope bioscience, AZ Therapies, Cerecin, and others

*
Key Alzheimer's Disease Therapies: BAN2401, Gantenerumab, ALZT-OP1, Bryostatin-1, ALZT-OP1, Tricaprilin

*
The Alzheimer's Disease epidemiology based on gender analyzed that more women than men have Alzheimer's or other dementias

Alzheimer's Disease Overview

Alzheimer's disease is a progressive neurological disorder that causes memory loss, confusion, and changes in behavior. It is the most common cause of dementia, affecting cognitive function and daily activities. The disease is characterized by the accumulation of abnormal protein plaques and tangles in the brain, which disrupt communication between nerve cells. Symptoms usually develop slowly and worsen over time, with individuals experiencing difficulty in remembering recent events, solving problems, and performing routine tasks. While there is no cure, treatments can help manage symptoms and improve quality of life. Alzheimer's disease primarily affects older adults, though early-onset cases can occur.

Get a Free sample for the Alzheimer's Disease Market Report:

https://www.delveinsight.com/report-store/alzheimers-disease-ad-market [https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Alzheimer's Disease Market

The dynamics of the Alzheimer's Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

"Of the emerging therapies, the most anticipated product to get launched is BAN2401. Apart from this, several other molecules are in early clinical stage or completed clinical studies such as ALZT-OP1, Gantenerumab, Brexpiprazole, and others."

Alzheimer's Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alzheimer's Disease Epidemiology Segmentation:

The Alzheimer's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Alzheimer's Disease

*
Prevalent Cases of Alzheimer's Disease by severity

*
Gender-specific Prevalence of Alzheimer's Disease

*
Diagnosed Cases of Episodic and Chronic Alzheimer's Disease

Download the report to understand which factors are driving Alzheimer's Disease epidemiology trends @ Alzheimer's Disease Epidemiological Insights [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Alzheimer's Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alzheimer's Disease market or expected to get launched during the study period. The analysis covers Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Alzheimer's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alzheimer's Disease Therapies and Key Companies

*
BAN2401: Eisai Inc.

*
Gantenerumab: Hoffmann-La Roche

*
ALZT-OP1: AZ Therapies

*
Bryostatin-1: Neurotrope bioscience

*
ALZT-OP1: AZ Therapies

*
Tricaprilin: Cerecin

To know more about Alzheimer's Disease treatment, visit @ Alzheimer's Disease Medications [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Alzheimer's Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Alzheimer's Disease Companies: Eisai Inc., Hoffmann-La Roche, AZ Therapies, Neurotrope bioscience, AZ Therapies, Cerecin, and others

*
Key Alzheimer's Disease Therapies: BAN2401, Gantenerumab, ALZT-OP1, Bryostatin-1, ALZT-OP1, Tricaprilin, and others

*
Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies

*
Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Alzheimer's Disease Market Access and Reimbursement

Discover more about therapies set to grab major Alzheimer's Disease market share @ Alzheimer's Disease market forecast [https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Alzheimer's Disease Market Report Introduction

2. Executive Summary for Alzheimer's Disease

3. SWOT analysis of Alzheimer's Disease

4. Alzheimer's Disease Patient Share (%) Overview at a Glance

5. Alzheimer's Disease Market Overview at a Glance

6. Alzheimer's Disease Disease Background and Overview

7. Alzheimer's Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Alzheimer's Disease

9. Alzheimer's Disease Current Treatment and Medical Practices

10. Alzheimer's Disease Unmet Needs

11. Alzheimer's Disease Emerging Therapies

12. Alzheimer's Disease Market Outlook

13. Country-Wise Alzheimer's Disease Market Analysis (2020-2034)

14. Alzheimer's Disease Market Access and Reimbursement of Therapies

15. Alzheimer's Disease Market Drivers

16. Alzheimer's Disease Market Barriers

17. Alzheimer's Disease Appendix

18. Alzheimer's Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alzheimers-disease-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-eisai-hoffmannla-roche-az-therapies-neurotrope-bioscience-az-therapies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.